Asked by: Mike Martin (Liberal Democrat - Tunbridge Wells)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to extend NHS eligibility for the Shingrix shingles vaccine to older adults who previously received Zostavax.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Joint Committee on Vaccination and Immunisation (JCVI) is an independent departmental expert committee which advises the Government on matters related to vaccination and immunisation.
In November 2024, the JCVI provided advice to the Government on eligibility for the shingles vaccination programme. This included advice that the Government should consider expanding the shingles vaccination offer to include older adult cohorts aged 80 years old and over, regardless of whether these older individuals have previously been eligible for, or have been vaccinated with, Zostavax. The Department is carefully considering this advice as it sets the policy on who should be offered shingles vaccinations.
Asked by: Mike Martin (Liberal Democrat - Tunbridge Wells)
Question to the Department for Education:
To ask the Secretary of State for Education, what recent discussions she has had with local authorities and employer groups on the availability of work‑experience placements for Year 10 pupils; and what steps she is taking to ensure adequate placements in all areas.
Answered by Georgia Gould - Minister of State (Education)
The government set out its vision for reforming work experience in the 2025 careers statutory guidance. Every pupil will have access to 2 weeks’ worth of multiple and varied workplace experiences throughout key stages 3 and 4.
According to the Careers & Enterprise Company (CEC) Compass+ self-assessment tool, the majority of students in 74% schools and colleges had an experience of the workplace in the 2024/25 academic year. Note this data does not capture duration.
The department funds the CEC to work with local areas and engage employers to deliver this commitment. CEC’s careers hubs work in partnership with mayoral strategic authorities and local authorities resulting in stronger career provision and increased employer engagement, locally. Findings from a recent pilot found that careers hubs, working with local authorities and mayoral strategic authorities, successfully coordinated work experience provision across multiple schools and employers, reducing duplication and widening access.
Regionally, careers hubs work with cornerstone employer groups, who represent the local labour market and support the region's strategic employment engagement. Nationally, CEC holds strategic partnerships with employer groups, sector and representative bodies supporting all employers to deliver workplace experiences.
Asked by: Mike Martin (Liberal Democrat - Tunbridge Wells)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for NHS use; and whether he plans to review the CAR‑T delivery tariff to ensure continued access to treatments.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cancer Drugs Fund. NICE’s draft guidance, published in December, does not recommend it as a clinically and cost-effective use of NHS resources. The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients with mantle cell lymphoma will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
The CAR-T delivery tariff reflects the costs which the NHS incurs for delivering CAR-T therapy. The tariff was updated for the start of the 2024/25 financial year following a planned costing review involving all CAR-T providers in England. This enabled the tariff to be updated with the benefit of the significant delivery experience that can be drawn on having first routinely introduced CAR-T in the NHS in 2023. Other than considering an appropriate inflationary uplift on an annual basis, in line with usual practice, there are no plans to further review the tariff at this time. Other CAR-T therapies have been recommended for routine NHS adoption in England by NICE based on an assessment of clinical and cost effectiveness that reflects the existing CAR-T delivery tariff, most recently obecabtagene autoleucel for acute lymphoblastic leukaemia.